Preclinical development of human CMV vaccines

人CMV疫苗的临床前开发

基本信息

  • 批准号:
    8075528
  • 负责人:
  • 金额:
    $ 77.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-06-01 至 2015-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Human cytomegalovirus (CMV) is the major infectious cause of birth defects in the United States. Recent demonstration that the glycoprotein B (gB)/MF59 vaccine has 50% efficacy in protecting women against primary CMV infection is a landmark in CMV vaccine research. However, 50% efficacy would be insufficient for vaccine licensure. Thus, the challenge now is to determine what can be added to a gB-based vaccine to increase efficacy to an acceptable level. Recent work from our laboratory indicates that an important component of humoral immunity is lacking from human antibody responses to the gB/MF59 vaccine. We showed that CMV seropositive people have high levels of antibodies that neutralize viral entry into epithelial cells. The gB/MF59 vaccine, however, fell far short of inducing the levels of epithelial entry neutralizing activities found in seropositive sera. We hypothesize that a vaccine capable of eliciting both gB- specific antibodies and antibodies that neutralize epithelial entry will have a significantly higher efficacy in preventing primary infection than that of the gB/MF59 vaccine. The epitopes that are targeted by the epithelial entry-specific neutralizing antibodies found in human CMV seropositive sera are unknown, but a strong case can be made for epitopes within a recently discovered virion glycoprotein complex consisting of gH, gL, UL128, UL130, and UL131 (gH/gL/UL128-131). This complex is essential for efficient viral entry into epithelial and endothelial cells but dispensable for entry into fibroblasts, and animal antibodies raised to epitopes within UL128, UL130, or UL131 specifically neutralize epithelial and/or endothelial entry. We therefore propose that vaccine strategies to elicit antibodies to epitopes within the gH/gL/UL128-131 complex will result in potent epithelial entry neutralizing responses. We have partnered with Vical Inc. to develop and evaluate immunization strategies that incorporate DNA expression vectors, recombinant subunit proteins/complexes, and inactivated virions. We will evaluate these approaches for their relative ability to elicit potent epithelial entry neutralizing responses in small animals. Optimal candidate strategies will be further evaluated for compatibility with established gB-based vaccine approaches. The results of the proposed studies will produce candidates ready for clinical development. Human cytomegalovirus (CMV) is the major infectious cause of birth defects in the United States. We recently found that natural infection by CMV elicits neutralizing antibodies that block viral entry into both fibroblasts and epithelial cells, while current candidate vaccines are deficient in eliciting antibodies that block epithelial cell entry. The aim of this project is to develop vaccine candidates that in animals elicit antibodies that block CMV entry into both cells types. Such candidates are anticipated to have improved efficacy over existing candidate vaccines and will be suitable for subsequent clinical development.
描述(由申请人提供): 人巨细胞病毒(CMV)是美国出生缺陷的主要感染原因。最近证明,糖蛋白B(gB)/MF 59疫苗在保护妇女免受原发性CMV感染方面具有50%的功效,这是CMV疫苗研究中的一个里程碑。然而,50%的效力不足以获得疫苗许可。因此,现在的挑战是确定可以添加到基于gB的疫苗中以将效力提高到可接受的水平。我们实验室最近的工作表明,体液免疫的一个重要组成部分是缺乏从人抗体反应的gB/MF 59疫苗。我们发现,CMV血清阳性的人有高水平的抗体,中和病毒进入上皮细胞。然而,gB/MF 59疫苗远远不能诱导血清阳性血清中发现的上皮进入中和活性水平。我们假设能够引发gB特异性抗体和中和上皮进入的抗体的疫苗在预防原发性感染方面将具有比gB/MF 59疫苗显著更高的功效。在人CMV血清阳性血清中发现的上皮入口特异性中和抗体靶向的表位尚不清楚,但最近发现的由gH、gL、UL 128、UL 130和UL 131组成的病毒体糖蛋白复合物(gH/gL/UL 128 -131)内的表位是一个强有力的例子。该复合物对于病毒有效进入上皮和内皮细胞是必需的,但对于进入成纤维细胞是必需的,并且针对UL 128、UL 130或UL 131内的表位产生的动物抗体特异性地中和上皮和/或内皮细胞的进入。因此,我们提出,疫苗策略,以引发抗体的gH/gL/UL 128 -131复合物内的表位将导致有效的上皮进入中和反应。我们与Vical Inc.合作。开发和评估包含DNA表达载体、重组亚单位蛋白/复合物和灭活病毒粒子的免疫策略。我们将评估这些方法在小动物中引起有效上皮进入中和反应的相对能力。将进一步评价最佳候选策略与已建立的基于gB的疫苗方法的兼容性。拟议研究的结果将产生可用于临床开发的候选药物。人巨细胞病毒(CMV)是美国出生缺陷的主要感染原因。我们最近发现,自然感染CMV激发中和抗体,阻止病毒进入成纤维细胞和上皮细胞,而目前的候选疫苗缺乏激发抗体,阻止上皮细胞进入。该项目的目的是开发候选疫苗,在动物中引发抗体,阻止CMV进入两种细胞类型。预计这些候选疫苗的疗效将优于现有的候选疫苗,并将适用于后续的临床开发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael A McVoy其他文献

Michael A McVoy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael A McVoy', 18)}}的其他基金

An HBC-vectored peptide-based cytomegalovirus vaccine
HBC 载体肽基巨细胞病毒疫苗
  • 批准号:
    8224073
  • 财政年份:
    2012
  • 资助金额:
    $ 77.39万
  • 项目类别:
An HBC-vectored peptide-based cytomegalovirus vaccine
HBC 载体肽基巨细胞病毒疫苗
  • 批准号:
    8546974
  • 财政年份:
    2012
  • 资助金额:
    $ 77.39万
  • 项目类别:
Preclinical development of human CMV vaccines
人CMV疫苗的临床前开发
  • 批准号:
    8277428
  • 财政年份:
    2010
  • 资助金额:
    $ 77.39万
  • 项目类别:
Preclinical development of human CMV vaccines
人CMV疫苗的临床前开发
  • 批准号:
    8468987
  • 财政年份:
    2010
  • 资助金额:
    $ 77.39万
  • 项目类别:
Preclinical development of human CMV vaccines
人CMV疫苗的临床前开发
  • 批准号:
    8663177
  • 财政年份:
    2010
  • 资助金额:
    $ 77.39万
  • 项目类别:
Preclinical development of human CMV vaccines
人CMV疫苗的临床前开发
  • 批准号:
    8434537
  • 财政年份:
    2010
  • 资助金额:
    $ 77.39万
  • 项目类别:
Preclinical development of human CMV vaccines
人CMV疫苗的临床前开发
  • 批准号:
    7903020
  • 财政年份:
    2010
  • 资助金额:
    $ 77.39万
  • 项目类别:
Guinea pig cytomegalovirus as a model for vaccines that target endocytic entry
豚鼠巨细胞病毒作为靶向内吞进入的疫苗模型
  • 批准号:
    7860357
  • 财政年份:
    2009
  • 资助金额:
    $ 77.39万
  • 项目类别:
Guinea pig cytomegalovirus as a model for vaccines that target endocytic entry
豚鼠巨细胞病毒作为靶向内吞进入的疫苗模型
  • 批准号:
    7707780
  • 财政年份:
    2009
  • 资助金额:
    $ 77.39万
  • 项目类别:
Ability of CMV Vaccines to Induce Antibodies that Block Endocytic Entry
CMV 疫苗诱导抗体阻止内吞进入的能力
  • 批准号:
    7670404
  • 财政年份:
    2008
  • 资助金额:
    $ 77.39万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 77.39万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 77.39万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 77.39万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 77.39万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 77.39万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 77.39万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 77.39万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 77.39万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 77.39万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 77.39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了